速递｜司美格鲁肽新适应症，在中国获批上市！

Core Viewpoint - The approval of semaglutide injection for cardiovascular indications in China marks a significant expansion from its initial use solely for weight management to include cardiovascular outcome management, demonstrating dual clinical value in weight management and cardiovascular risk control [5][6]. Group 1: Clinical Efficacy - Clinical studies indicate that approximately one-third of patients can achieve a weight loss exceeding 20%, while the risk of major adverse cardiovascular events is reduced by about 20% [5]. - The SELECT study, the largest cardiovascular outcome trial for overweight or obese patients with cardiovascular disease, included 17,604 participants across 41 countries and demonstrated that semaglutide significantly lowers the risk of major adverse cardiovascular events by 20%, cardiovascular death by 15%, heart failure-related composite endpoints by 18%, and all-cause mortality by 19% [6][7]. Group 2: Consistency of Benefits - The cardiovascular benefits of semaglutide were consistent across various subgroups, regardless of baseline age, gender, population characteristics, body mass index, or degree of renal impairment, indicating its broad applicability [7]. - Secondary analyses of the SELECT data revealed that semaglutide exhibits cardiac protective effects early in treatment, prior to significant weight loss, suggesting that its cardiovascular benefits may be independent of weight changes [7]. Group 3: Real-World Evidence - A retrospective observational study (STEER) showed that patients with overweight or obesity and diagnosed cardiovascular disease who continued semaglutide treatment had a 57% lower risk of myocardial infarction, stroke, and all-cause mortality compared to those treated with tirzepatide, further supporting semaglutide's unique advantages in cardiovascular protection [7]. - The existing evidence suggests that the cardiovascular protective effects of semaglutide may have molecular specificity, and these benefits cannot be simply extrapolated to other GLP-1 or GIP/GLP-1 class drugs, providing clearer evidence-based guidance for medication selection in patients with obesity and cardiovascular disease [7].